PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.60B
5Y Perf.-78.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRGO vs JNJ
Revenue, margins, valuation, and 5-year total return — side by side.
JNJ
Johnson & Johnson
Drug Manufacturers - General
Market Cap$543.64B
5Y Perf.+51.7%
PRGO vs JNJ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRGO | JNJ |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Market Cap | $1.60B | $543.64B |
| Revenue (TTM) | $4.25B | $92.15B |
| Net Income (TTM) | $-1.43B | $25.12B |
| Gross Margin | 35.1% | 68.1% |
| Operating Margin | -26.4% | 26.1% |
| Forward P/E | 5.5x | 19.5x |
| Total Debt | $37M | $36.63B |
| Cash & Equiv. | $532M | $24.11B |
PRGO vs JNJ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRGO
JNJ
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Perrigo Company plc (PRGO) | 100 | 21.3 | -78.7% |
| Johnson & Johnson (JNJ) | 100 | 151.7 | +51.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRGO vs JNJ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JNJ leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
PRGO
Perrigo Company plc
The Defensive Pick
PRGO is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.18, Low D/E 1.2%, current ratio 2.76x
- Beta 1.18, yield 9.9%, current ratio 2.76x
- Lower P/E (5.5x vs 19.5x)
Best for: sleep-well-at-night and defensive
JNJ
Johnson & Johnson
The Income Pick
JNJ carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 36 yrs, beta 0.06, yield 2.2%
- Rev growth 4.3%, EPS growth -57.8%, 3Y rev CAGR 4.1%
- 136.8% 10Y total return vs PRGO's -78.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | JNJ | 4.3% revenue growth vs PRGO's -2.8% |
| Value | PRGO | Lower P/E (5.5x vs 19.5x) |
| Quality / Margins | JNJ | 27.3% margin vs PRGO's -33.5% |
| Stability / Safety | JNJ | Beta 0.06 vs PRGO's 1.18 |
| Dividends | PRGO | 9.9% yield, 10-year raise streak, vs JNJ's 2.2% |
| Momentum (1Y) | JNJ | +48.9% vs PRGO's -49.3% |
| Efficiency (ROA) | JNJ | 13.0% ROA vs PRGO's -16.7%, ROIC 20.7% vs -17.1% |
PRGO vs JNJ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
PRGO vs JNJ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJNJLAGGINGPRGO
PRGOPerrigo Company plc
1leads
JNJJohnson & Johnson
4leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JNJ6/6
Valuation MetricsMultiples, price ratios, and targets
PRGO5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JNJ5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
JNJ6/6
Risk & VolatilityBeta, volatility, and downside exposure
JNJ2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
JNJ leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JNJ is the larger business by revenue, generating $92.1B annually — 21.7x PRGO's $4.3B. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to PRGO's -33.5%. On growth, JNJ holds the edge at +6.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| RevenueTrailing 12 months | $4.3B | $92.1B |
| EBITDAEarnings before interest/tax | -$1.1B | $31.4B |
| Net IncomeAfter-tax profit | -$1.4B | $25.1B |
| Free Cash FlowCash after capex | $145M | $19.1B |
| Gross MarginGross profit ÷ Revenue | +35.1% | +68.1% |
| Operating MarginEBIT ÷ Revenue | -26.4% | +26.1% |
| Net MarginNet income ÷ Revenue | -33.5% | +27.3% |
| FCF MarginFCF ÷ Revenue | +3.4% | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.5% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -31.0% | +91.0% |
JNJ leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| Market CapShares × price | $1.6B | $543.6B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $556.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.13x | 38.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 5.52x | 19.47x |
| PEG RatioP/E ÷ EPS growth rate | — | 34.64x |
| EV / EBITDAEnterprise value multiple | — | 18.86x |
| Price / SalesMarket cap ÷ Revenue | 0.38x | 6.12x |
| Price / BookPrice ÷ Book value/share | 0.55x | 7.67x |
| Price / FCFMarket cap ÷ FCF | 11.04x | 27.40x |
PRGO leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
JNJ leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
JNJ delivers a 31.7% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-49 for PRGO. PRGO carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JNJ's 0.51x.
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| ROE (TTM)Return on equity | -48.6% | +31.7% |
| ROA (TTM)Return on assets | -16.7% | +13.0% |
| ROICReturn on invested capital | -17.1% | +20.7% |
| ROCEReturn on capital employed | -13.9% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.51x |
| Net DebtTotal debt minus cash | -$495M | $12.5B |
| Cash & Equiv.Liquid assets | $532M | $24.1B |
| Total DebtShort + long-term debt | $37M | $36.6B |
| Interest CoverageEBIT ÷ Interest expense | -6.91x | 48.23x |
JNJ leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
JNJ leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JNJ five years ago would be worth $14,920 today (with dividends reinvested), compared to $4,057 for PRGO. Over the past 12 months, JNJ leads with a +48.9% total return vs PRGO's -49.3%. The 3-year compound annual growth rate (CAGR) favors JNJ at 13.9% vs PRGO's -25.1% — a key indicator of consistent wealth creation.
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| YTD ReturnYear-to-date | -14.1% | +9.4% |
| 1-Year ReturnPast 12 months | -49.3% | +48.9% |
| 3-Year ReturnCumulative with dividends | -58.0% | +47.8% |
| 5-Year ReturnCumulative with dividends | -59.4% | +49.2% |
| 10-Year ReturnCumulative with dividends | -78.5% | +136.8% |
| CAGR (3Y)Annualised 3-year return | -25.1% | +13.9% |
JNJ leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
JNJ leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JNJ is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JNJ currently trades 89.6% from its 52-week high vs PRGO's 40.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.18x | 0.06x |
| 52-Week HighHighest price in past year | $28.44 | $251.71 |
| 52-Week LowLowest price in past year | $9.23 | $146.12 |
| % of 52W HighCurrent price vs 52-week peak | +40.9% | +89.6% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 35.3 |
| Avg Volume (50D)Average daily shares traded | 3.3M | 7.0M |
JNJ leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates PRGO as "Hold" and JNJ as "Buy". Consensus price targets imply 71.8% upside for PRGO (target: $20) vs 10.5% for JNJ (target: $249). For income investors, PRGO offers the higher dividend yield at 9.88% vs JNJ's 2.16%.
| Metric | PRGOPerrigo Company p… | JNJJohnson & Johnson |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $20.00 | $249.27 |
| # AnalystsCovering analysts | 36 | 40 |
| Dividend YieldAnnual dividend ÷ price | +9.9% | +2.2% |
| Dividend StreakConsecutive years of raises | 10 | 36 |
| Dividend / ShareAnnual DPS | $1.15 | $4.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.
Key Takeaway
JNJ leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 1 tied.
Best OverallJohnson & Johnson (JNJ)Leads 4 of 6 categories
Loading custom metrics...
PRGO vs JNJ: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PRGO or JNJ a better buy right now?
For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 4.
3% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Johnson & Johnson (JNJ) offers the better valuation at 39. 0x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRGO or JNJ?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PRGO or JNJ?
Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +49.
2%, compared to -59. 4% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: JNJ returned +136. 8% versus PRGO's -78. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRGO or JNJ?
By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.
06β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 1972% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 1% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.
05Which is growing faster — PRGO or JNJ?
By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 4.
3% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Johnson & Johnson grew EPS -57. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, JNJ leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRGO or JNJ?
Johnson & Johnson (JNJ) is the more profitable company, earning 15.
8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -26. 4% for PRGO. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRGO or JNJ more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 19. 5x for Johnson & Johnson — 13. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 71. 8% to $20. 00.
08Which pays a better dividend — PRGO or JNJ?
All stocks in this comparison pay dividends.
Perrigo Company plc (PRGO) offers the highest yield at 9. 9%, versus 2. 2% for Johnson & Johnson (JNJ).
09Is PRGO or JNJ better for a retirement portfolio?
For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
06), 2. 2% yield, +136. 8% 10Y return). Both have compounded well over 10 years (JNJ: +136. 8%, PRGO: -78. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRGO and JNJ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PRGO is a small-cap income-oriented stock; JNJ is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(PRGO: -2.5% · JNJ: 6.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.